234 related articles for article (PubMed ID: 27156362)
21. Protein-glycan interactions as targets of intravenous/subcutaneous immunoglobulin (IVIg/SCIg) preparations.
von Gunten S
Clin Exp Immunol; 2014 Dec; 178 Suppl 1(Suppl 1):151-2. PubMed ID: 25546801
[No Abstract] [Full Text] [Related]
22. 7th International Immunoglobulin Conference: Poster presentations.
Warnatz K; Ballow M; Stangel M; Bril V
Clin Exp Immunol; 2014 Dec; 178 Suppl 1(Suppl 1):162. PubMed ID: 25546805
[TBL] [Abstract][Full Text] [Related]
23. Clinical experiences in primary and secondary immunodeficiencies and immune-mediated conditions using Gammanorm(®).
Gardulf A
Immunotherapy; 2016 May; 8(5):633-47. PubMed ID: 27020964
[TBL] [Abstract][Full Text] [Related]
24. Utilization of intravenous or subcutaneous immunoglobulins in secondary immune deficiency (ULTIMATE): A retrospective multicenter study.
Legendre P; Chahwan D; Marjanovic Z; Vignon M; Hermine O; Lortholary O; Morelle G; Darrodes M; Kahn JE; Ouzegdouh M; Chaibi P; Montestruc F; Caumont-Prim A; Le Jouan M; Hassani Y; Godeau B; Durand-Zaleski I; Mouthon L
Clin Immunol; 2020 Jun; 215():108419. PubMed ID: 32289463
[TBL] [Abstract][Full Text] [Related]
25. Update on the use of immunoglobulin in human disease: A review of evidence.
Perez EE; Orange JS; Bonilla F; Chinen J; Chinn IK; Dorsey M; El-Gamal Y; Harville TO; Hossny E; Mazer B; Nelson R; Secord E; Jordan SC; Stiehm ER; Vo AA; Ballow M
J Allergy Clin Immunol; 2017 Mar; 139(3S):S1-S46. PubMed ID: 28041678
[TBL] [Abstract][Full Text] [Related]
26. Switching Patients to Home-Based Subcutaneous Immunoglobulin: an Economic Evaluation of an Interprofessional Drug Therapy Management Program.
Perraudin C; Bourdin A; Spertini F; Berger J; Bugnon O
J Clin Immunol; 2016 Jul; 36(5):502-10. PubMed ID: 27139500
[TBL] [Abstract][Full Text] [Related]
27. Choices in IgG replacement therapy for primary immune deficiency diseases: subcutaneous IgG vs. intravenous IgG and selecting an optimal dose.
Berger M
Curr Opin Allergy Clin Immunol; 2011 Dec; 11(6):532-8. PubMed ID: 21971330
[TBL] [Abstract][Full Text] [Related]
28. 7th International Immunoglobulin Conference: Immunoglobulin in clinical practice.
Shapiro RS; Borte M
Clin Exp Immunol; 2014 Dec; 178 Suppl 1(Suppl 1):65-6. PubMed ID: 25546766
[TBL] [Abstract][Full Text] [Related]
29. Facilitated Subcutaneous Immunoglobulin Treatment Increases the Quality of Life and Decreases the Number of Infections and Hospitalizations in Children with Primary Immunodeficiencies.
Erbaş Açıcı N; Topyildiz E; Aygün A; Geyik M; Edeer Karaca N; Aksu G; Kutukculer N
Int Arch Allergy Immunol; 2024; 185(4):382-391. PubMed ID: 38246144
[TBL] [Abstract][Full Text] [Related]
30. Human immune globulin 10% with recombinant human hyaluronidase in multifocal motor neuropathy.
Herraets IJT; Bakers JNE; van Eijk RPA; Goedee HS; van der Pol WL; van den Berg LH
J Neurol; 2019 Nov; 266(11):2734-2742. PubMed ID: 31325017
[TBL] [Abstract][Full Text] [Related]
31. [Subcutaneous immunoglobulin substitution and therapy].
Gulácsy V; Maródi L
Orv Hetil; 2011 Jan; 152(2):64-7. PubMed ID: 21177233
[TBL] [Abstract][Full Text] [Related]
32. Management of secondary immune deficiencies: what is the role of immunoglobulins?
Mouthon L; Fermand JP; Gottenberg JE
Curr Opin Allergy Clin Immunol; 2013 Jul; 13 Suppl 2():S56-67. PubMed ID: 23873315
[No Abstract] [Full Text] [Related]
33. A systematic literature review of the effects of immunoglobulin replacement therapy on the burden of secondary immunodeficiency diseases associated with hematological malignancies and stem cell transplants.
Monleón Bonet C; Waser N; Cheng K; Tzivelekis S; Edgar JDM; Sánchez-Ramón S
Expert Rev Clin Immunol; 2020 Sep; 16(9):911-921. PubMed ID: 32783541
[TBL] [Abstract][Full Text] [Related]
34. A French observational study describing the use of human polyvalent immunoglobulins in hematological malignancy-associated secondary immunodeficiency.
Benbrahim O; Viallard JF; Choquet S; Royer B; Bauduer F; Decaux O; Crave JC; Fardini Y; Clerson P; Lévy V
Eur J Haematol; 2018 Jul; 101(1):48-56. PubMed ID: 29644723
[TBL] [Abstract][Full Text] [Related]
35. Facilitated Subcutaneous Immunoglobulin (fSCIg) in Autoimmune Cytopenias Associated with Common Variable Immunodeficiency.
Pedini V; Savore I; Danieli MG
Isr Med Assoc J; 2017 Jul; 19(7):420-423. PubMed ID: 28786256
[TBL] [Abstract][Full Text] [Related]
36. A Phase 1 Open-Label Study to Assess the Tolerability, Safety, and Immunogenicity of Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 20% in Healthy Adults.
Nagy A; Duff K; Bauer A; Okonneh F; Rondon JC; Yel L; Li Z
J Clin Immunol; 2023 Dec; 44(1):28. PubMed ID: 38129731
[TBL] [Abstract][Full Text] [Related]
37. Using intravenous immunoglobulin (IVIG) to treat patients with primary immune deficiency disease.
Bonagura VR
J Clin Immunol; 2013 Jan; 33 Suppl 2():S90-4. PubMed ID: 23271459
[TBL] [Abstract][Full Text] [Related]
38. Privigen® has similar pharmacokinetic properties in primary and secondary immune deficiency.
Tortorici MA; Lawo JP; Weide R; Jochems J; Puli S; Hofmann J; Pfruender D; Rojavin MA
Int Immunopharmacol; 2019 Jan; 66():119-126. PubMed ID: 30447530
[TBL] [Abstract][Full Text] [Related]
39. 7th International Immunoglobulin Conference: Immunoglobulin in clinical practice.
Shapiro RS; Borte M
Clin Exp Immunol; 2014 Dec; 178 Suppl 1(Suppl 1):86. PubMed ID: 25546773
[TBL] [Abstract][Full Text] [Related]
40. Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home.
Gardulf A; Nicolay U; Math D; Asensio O; Bernatowska E; Böck A; Costa-Carvalho BT; Granert C; Haag S; Hernández D; Kiessling P; Kus J; Matamoros N; Niehues T; Schmidt S; Schulze I; Borte M
J Allergy Clin Immunol; 2004 Oct; 114(4):936-42. PubMed ID: 15480339
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
